What happens if I overdose Clz?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local, or emergency room immediately. Clz suppositories may be harmful if swallowed.
Proper storage of Clz suppositories:
Store Clz suppositories at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store in a tightly closed container away from heat, moisture, and light. Avoid temperatures above 86 degrees F (30 degrees C) and high humidity. Do not store in the bathroom. Keep Clz suppositories out of the reach of children and away from pets.
Overdose of Clz in details
Clz is intended for topical use only. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), rinse affected area with copious amounts of cool water.
Topically applied Clz phosphate can be absorbed in sufficient amounts to produce systemic effects.
In the event of overdosage, general symptomatic and supportive measures are indicated as required.
What should I avoid while taking Clz?
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking Clz topical and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.
Do not use other medicated skin products unless your doctor has told you to. Avoid using skin products that can cause irritation, such as harsh soaps, shampoos, or skin cleansers, hair coloring or permanent chemicals, hair removers or waxes, or skin products with alcohol, spices, astringents, or lime.
Avoid getting this medication in your eyes, nose, mouth, rectum, or vagina. If this does happen, rinse with water. Do not use Clz topical on sunburned, windburned, dry, chapped, irritated, or broken skin.
Do not smoke while using Clz topical foam, or immediately after applying it. The contents of the foam canister are flammable.
Clz warnings
Colitis
Systemic absorption of Clz has been demonstrated following topical use of this product. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical Clz. If significant diarrhea occurs, Clz Foam should be discontinued.
Severe colitis has occurred following oral or parenteral administration of Clz with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
Irritation
Clz Foam can cause irritation. Concomitant topical acne thereapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritation or dermatitis occurs, Clz should be discontinued.
Avoid contact of Clz Foam with eyes, mouth, lips, other mucous membranes or areas of broken skin. If contact occurs, rinse thoroughly with water.
Clz Foam should be prescribed with caution in atopic individuals.
What should I discuss with my healthcare provider before taking Clz?
Some medical conditions may interact with Clz suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have diarrhea, or a history of liver problems or stomach or bowel problems (eg, colitis)
- if you have been very ill
Some MEDICINES MAY INTERACT with Clz suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Nondepolarizing muscle relaxants (eg, vecuronium) or succinylcholine because the risk of their side effects may be increased by Clz suspension
- Erythromycin because it may decrease Clz suspension's effectiveness
This may not be a complete list of all interactions that may occur. Ask your health care provider if Clz suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Clz precautions
Colitis
Systemic absorption of Clz has been demonstrated following topical use of this product. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical Clz. If significant diarrhea occurs, Clz Foam should be discontinued.
Severe colitis has occurred following oral or parenteral administration of Clz with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
Irritation
Clz Foam can cause irritation. Concomitant topical acne therapy should be used with caution since a possible cumulative irritancy effect may occur, especially with the use of peeling, desquamating, or abrasive agents. If irritation or dermatitis occurs, Clz should be discontinued.
Avoid contact of Clz Foam with eyes, mouth, lips, other mucous membranes or areas of broken skin. If contact occurs, rinse thoroughly with water.
Clz Foam should be prescribed with caution in atopic individuals.
Patient Counseling Information
Instructions for Use
- Patients should be advised to wash their skin with mild soap and allow it to dry before applying Clz Foam.
- Patients should use enough Clz Foam to cover the face and to apply once daily.
- Patients should dispense Clz Foam directly into the cap or onto a cool surface.
- Patients should wash their hands after applying Clz Foam.
Skin Irritation
Clz Foam may cause irritation such as erythema, scaling, itching, burning, or stinging. Patients should be advised to discontinue use if excessive irritancy or dermatitis occur.
Colitis
In the event a patient treated with Clz Foam experiences severe diarrhea or gastrointestinal discomfort, Clz Foam should be discontinued and a physician should be contacted.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment of Fertility
The carcinogenicity of a 1.2% Clz phosphate gel similar to Clz Foam was evaluated by daily application to mice for two years. The daily doses used in this study were approximately 3 and 15 times higher than the human dose of Clz phosphate from 5 milliliters of Clz Foam, assuming complete absorption and based on a body surface area comparison. No significant increase in tumors was noted in the treated animals.
A 1.2% Clz phosphate gel similar to Clz Foam caused a statistically significant shortening of the median time to tumor onset in a study in hairless mice in which tumors were induced by exposure to simulated sunlight.
Genotoxicity tests performed included a rat micronucleus test and an Ames Salmonella reversion test. Both tests were negative.
Reproduction studies in rats using oral doses of Clz hydrochloride and Clz palmitate hydrochloride have revealed no evidence of impaired fertility.
Use In Specific Populations
Pregnancy
Pregnancy Category B: There are no adequate and well-controlled studies in pregnant women treated with Clz Foam. Clz Foam should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus.
Reproduction studies have been performed in rats and mice using subcutaneous and oral doses of Clz phosphate, Clz hydrochloride and Clz palmitate hydrochloride. These studies revealed no evidence of fetal harm. The highest dose used in the rat and mouse teratogenicity studies was equivalent to a Clz phosphate dose of 432 mg/kg. For a rat, this dose is 84 fold higher, and for a mouse 42 fold higher, than the anticipated human dose of Clz phosphate from Clz Foam based on a mg/m² comparison.
Nursing Mothers
It is not known whether Clz is excreted in human milk following use of Clz Foam. However, orally and parenterally administered Clz has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
If used during lactation and Clz Foam is applied to the chest, care should be taken to avoid accidental ingestion by the infant.
Pediatric Use
Safety and effectiveness of Clz Foam in children under the age of 12 have not been studied.
Geriatric Use
The clinical study with Clz Foam did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects.
What happens if I miss a dose of Clz?
Apply the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to apply the medicine and skip the missed dose. Do not use extra medicine to make up the missed dose.
References
- DrugBank. "clindamycin". http://www.drugbank.ca/drugs/DB01190 (accessed September 17, 2018).
- MeSH. "Protein Synthesis Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
